Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 4/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 9/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.38 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.38 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoleucine SCHEMBL1965718 | 1.00 | SLC1A3 (0.41) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| Isoleucine SCHEMBL20913227 | 0.95 | SLC7A5 (0.44) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| Isoleucine SCHEMBL20913224 | 0.95 | SLC7A5 (0.44) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| Isoleucine SCHEMBL17582482 | 0.95 | SLC7A5 (0.44) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| Isoleucine SCHEMBL17582473 | 0.95 | SLC7A5 (0.44) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| Isoleucine SCHEMBL23645012 | 0.95 | SLC7A5 (0.44) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| Isoleucine SCHEMBL20913222 | 0.95 | SLC7A5 (0.44) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| Isoleucine SCHEMBL20913231 | 0.95 | SLC7A5 (0.44) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| Isoleucine SCHEMBL17582462 | 0.95 | SLC7A5 (0.44) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| Isoleucine SCHEMBL17582471 | 0.95 | SLC7A5 (0.44) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421892-A1 | CONTROL OF PROTEIN GLYCOSYLATION AND COMPOSITIONS AND METHODS RELATING THERETO | Pfizer Inc. (US) | 2012-02-29 | — | — | EP | claimed |
| WO-2010122460-A1 | CONTROL OF PROTEIN GLYCOSYLATION AND COMPOSITIONS AND METHODS RELATING THERETO | PFIZER INC. (US) | 2010-10-28 | — | — | WO | claimed |
| US-20090226456-A1 | screening methods for identifying agonists and antagonists of TNFR-6 alpha & -6 beta activity; diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders; cancer | HUMAN GENOME SCIENCES, INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-20060234285-A1 | For treating or preventing inflammatory diseases, autoimmune diseases, graft versus host disease (GVHD), allergis, asthma, and/or hepatitis; drug screening | HUMAN GENOME SCIENCES, INC. (US) | 2006-10-19 | — | — | US | claimed |
| US-6887848-B2 | Vascular endothelial growth factor variants | SCIOS, INC. (US) | 2005-05-03 | — | — | US | claimed |
| US-20030096754-A1 | Vascular endothelial growth factor variants | POLLITT N STEPHEN (US) | 2003-05-22 | — | — | US | claimed |
| US-6475796-B1 | Vascular endothelial growth factor variants | SCIOS, INC. | 2002-11-05 | — | — | US | claimed |
| EP-1183352-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR VARIANTS | SCIOS INC. (US) | 2002-03-06 | — | — | EP | claimed |
| WO-2000071713-A1 | VASCULAR ENDOTHELIAL GROWTH FACTOR VARIANTS | SCIOS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| US-5670356-A | LUCIFERASE GENES OF PHOTINUS, DNA SEQUENCES, NUCLEOTIDES AND GENETIC ENGINEERING | PROMEGA CORPORATION (US) | 1997-09-23 | — | — | US | claimed |
| EP-4237428-A2 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | Pfizer Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116615439-A | Coli composition and method thereof | 辉瑞大药厂 | 2023-08-18 | — | — | CN | disclosed |
| CN-115605498-A | Escherichia coli composition and method thereof | 辉瑞公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20230000966-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | PFIZER INC. | 2023-01-05 | — | — | US | disclosed |
| CN-114667343-A | Escherichia coli composition and method thereof | 辉瑞大药厂 | 2022-06-24 | — | — | CN | disclosed |
| WO-2010122460-A1 | CONTROL OF PROTEIN GLYCOSYLATION AND COMPOSITIONS AND METHODS RELATING THERETO | PFIZER INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-1809661-A4 | HUMAN INTERFERON-BETA MUTEIN | SHIN YOUNG KEE (KR) | 2008-02-06 | — | — | EP | disclosed |
| EP-1809661-A1 | HUMAN INTERFERON-BETA MUTEIN | Shin, Young Kee (KR) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006049423-A1 | HUMAN INTERFERON-BETA MUTEIN | SAMSUNG FINE CHEMICALS CO LTD (KR) | 2006-05-11 | — | — | WO | disclosed |
| US-5670356-A | LUCIFERASE GENES OF PHOTINUS, DNA SEQUENCES, NUCLEOTIDES AND GENETIC ENGINEERING | PROMEGA CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000966-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | MRPL21, ENGASE, DDOST | SLC1A3 4412/4885SLC1A2 4619/4885SLC1A1 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.